Payment overview · 2025
General Payments
$2,425.60
142 reported records · 24 companies
Healthcare provider profile · identity verified
C Mark Rose, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · RICHMOND, MO · NPI 1265408215
Verified facts
What the public records show
CMS Open Payments records show C Mark Rose, D.O. received $2,425.60 in general payments during 2025 across 142 reported records.
ABBVIE INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 270 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 226 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $395.71 | 16.3% | 36 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $326.96 | 13.5% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $255.08 | 10.5% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.11 | 7.7% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $166.18 | 6.8% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $161.05 | 6.6% | 11 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $152.73 | 6.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $146.10 | 6.0% | 11 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $140.72 | 5.8% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $97.11 | 4.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $84.19 | 3.5% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $57.44 | 2.4% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $36.93 | 1.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.85 | 1.4% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $23.94 | 1.0% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $23.36 | 1.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.12 | 0.9% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.03 | 0.9% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $19.04 | 0.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.15 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.96 | 0.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.69 | 0.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.06 | 0.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.09 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,425.60 | 142 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $326.96 | 10 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $323.27 | 26 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $255.08 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $161.05 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $161.05 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $152.73 | 11 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $140.72 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.06 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $108.14 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $97.11 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $93.01 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $91.22 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $89.85 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $84.19 | 4 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $78.65 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $72.44 | 10 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $67.18 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $66.27 | 8 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $57.44 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $57.20 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.93 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.85 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $32.65 | 3 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $23.94 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $23.36 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 205 Acute Care Normalized: hillrom vest system model 205 acute care |
Device | Baxter Healthcare | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.09 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $2.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 226 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 161 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 270 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
161 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
270 | 42 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
226 | 48 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 814 | 198 |
| Alprazolam | Alprazolam | 589 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 588 | 123 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 575 | 86 |
| Lisinopril | Lisinopril | 531 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 519 | 116 |
| Gabapentin | Gabapentin | 465 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 442 | 90 |
| Omeprazole | Omeprazole | 380 | 85 |
| Potassium Chloride | Potassium Chloride | 352 | 73 |
| Metformin Hcl | Metformin Hcl | 338 | 86 |
| Furosemide | Furosemide | 333 | 76 |
| Losartan Potassium | Losartan Potassium | 328 | 78 |
| Fluoxetine Hcl | Fluoxetine Hcl | 320 | 71 |
| Celecoxib | Celecoxib | 318 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 312 | 75 |
| Carvedilol | Carvedilol | 295 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 277 | 45 |
| Ozempic | Semaglutide | 270 | 42 |
| Montelukast Sodium | Montelukast Sodium | 263 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 260 | 64 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 250 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 243 | 58 |
| Tramadol Hcl | Tramadol Hcl | 233 | 60 |
| Trazodone Hcl | Trazodone Hcl | 227 | 46 |
| Eliquis | Apixaban | 226 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 217 | 50 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 212 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 211 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 186 | 51 |
| Allopurinol | Allopurinol | 182 | 41 |
| Lorazepam | Lorazepam | 167 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 166 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 34 |
| Azithromycin | Azithromycin | 163 | 135 |
| Jardiance | Empagliflozin | 161 | 32 |
| Meloxicam | Meloxicam | 159 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 156 | 21 |
| Sertraline Hcl | Sertraline Hcl | 146 | 31 |
| Oxycodone Hcl | Oxycodone Hcl | 144 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 143 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 135 | 33 |
| Methylprednisolone | Methylprednisolone | 128 | 106 |
| Pregabalin | Pregabalin | 124 | 24 |
| Simvastatin | Simvastatin | 122 | 35 |
| Famotidine | Famotidine | 116 | 31 |
| Prednisone | Prednisone | 113 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 111 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 111 | 28 |
| Spironolactone | Spironolactone | 110 | 26 |
| Baclofen | Baclofen | 104 | 19 |
| Clonazepam | Clonazepam | 104 | 18 |
| Chlorthalidone | Chlorthalidone | 101 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 21 |
| Januvia | Sitagliptin Phosphate | 92 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 88 | 16 |
| Warfarin Sodium | Warfarin Sodium | 81 | 15 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 80 | 20 |
| Xarelto | Rivaroxaban | 80 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 77 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 77 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 76 | 14 |
| Mounjaro | Tirzepatide | 73 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 72 | 13 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 70 | 15 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 69 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 16 |
| Ezetimibe | Ezetimibe | 68 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 67 | 18 |
| Buspirone Hcl | Buspirone Hcl | 65 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 57 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 17 |
| Diazepam | Diazepam | 61 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 58 | 15 |
| Mupirocin | Mupirocin | 57 | 39 |
| Naproxen | Naproxen | 55 | 17 |
| Glimepiride | Glimepiride | 53 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 53 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 12 |
| Amoxicillin | Amoxicillin | 50 | 37 |
| Benazepril Hcl | Benazepril Hcl | 48 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 47 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Nitroglycerin | Nitroglycerin | 46 | 26 |
| Aripiprazole | Aripiprazole | 45 | 12 |
| Chlorzoxazone | Chlorzoxazone | 45 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 45 | suppressed |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Novolog Flexpen | Insulin Aspart | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Estradiol | Estradiol | 44 | 15 |
| Torsemide | Torsemide | 44 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 43 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Dutasteride | Dutasteride | 41 | suppressed |
| Fenofibrate | Fenofibrate | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | suppressed |
| Temazepam | Temazepam | 39 | suppressed |
| Topiramate | Topiramate | 39 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 35 | suppressed |
| Digoxin | Digoxin | 35 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Clonidine | Clonidine | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Gemtesa | Vibegron | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Telmisartan | Telmisartan | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Vraylar | Cariprazine Hcl | 29 | suppressed |
| Westab Plus | Pnv,calcium 72/Iron/Folic Acid | 29 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 28 |
| Linzess | Linaclotide | 28 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 21 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 27 | suppressed |
| Fluconazole | Fluconazole | 26 | 18 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 16 |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 23 |
| Indomethacin | Indomethacin | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Risperidone | Risperidone | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 19 |
| Glipizide | Glipizide | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ergotamine-Caffeine | Ergotamine Tartrate/Caffeine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Uloric | Febuxostat | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,425.60 · 142 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APTIMA, AUSTEDO XR, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, Flexitouch Plus, GEMTESA, HETLIOZ, Hillrom - Vest System Model 205 Acute Care, INGREZZA, JARDIANCE, JOURNAVX, LEQVIO, MOUNJARO, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, THINPREP 2000 PROCESSOR, UBRELVY, VOQUEZNA, VRAYLAR, VYNDAMAX, Veozah, XIFAXAN, YUPELRI, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error